Perspective Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2401 ELLIOTT AVENUE, SEATTLE, WA, 98121
Mailing Address
2401 ELLIOTT AVENUE, SEATTLE, WA, 98121
Phone
206-676-0900
Fiscal Year End
1231
EIN
411458152
Financial Overview
FY2025
-$79.28M
Net Income
$341.10M
Total Assets
$290.67M
Stockholders' Equity
$61.58M
Cash & Equivalents
$-1.23
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 1, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Developing innovative targeted alpha-particle therapies (TATs) for various cancers, aiming for precise radiation delivery.
- Operates in the high-growth, high-risk biotechnology sector.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.